2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1990

Effectiveness and Durability of a Brief Multidisciplinary Treatment Program for Patients with Fibromyalgia
Abstract Number: 1517

Effectiveness and Retention Rate of Certolizumab Pegol in Spondyloarthritis. Real Life Data
Abstract Number: 2444

Effectiveness and Safety of CT-P13 in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis and Plaque Psoriasis: Observational Study in Republic of Korea
Abstract Number: 1684

Effectiveness and Safety of Tacrolimus Following Intravenous Cyclophosphamide Pulse Therapy As the Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease
Abstract Number: 2447

Effectiveness and Tolerability of Benepali in Rheumatoid Arthritis Patients Switched from Enbrel
Abstract Number: 1145

Effectiveness of a Multidisciplinary Gout Clinic on Timely Achievement of Serum Uric Acid Goals
Abstract Number: 845

Effectiveness of Brief Group Psychoanalytic Psychotherapy in Patients with Systemic Lupus Erythematosus and Follow-up
Abstract Number: 1516

Effectiveness of Certolizumab Pegol in Patients with Uveitis Associated to Spondyloarthritis Refractory to Other Tumour Necrosis Factor Inhibitors
Abstract Number: 2292

Effectiveness of Common Treatment Strategies for Juvenile Arthritis in Usual Practice: Results from the Research in Arthritis in Canadian Children Emphasizing Outcomes Cohort
Abstract Number: 611

Effectiveness of Early Adalimumab Therapy in Psoriatic Arthritis Patients from Reuma.Pt
Abstract Number: 934

Effectiveness of FX006 Intra-Articular Injection in Patients with Knee Osteoarthritis Who Present with and without Clinical Inflammation at Baseline: A Pooled Analysis of Data from 3 Double-Blind, Randomized, Parallel-Group Clinical Trials
Abstract Number: 1205

Effectiveness of Low-Dose Radiation Therapy on Symptoms in Knee Osteoarthritis: First Results of a Triple Blinded, Randomized Controlled Trial
Abstract Number: 2280

Effectiveness of Switching to Adalimumab As the Second- and Third-Line Biological Drug in Patients with Juvenile Idiopathic Arthritis
Abstract Number: 1093

Effectiveness of the Outreach Model for Rheumatology Specialty Clinics to On-Reserve First Nations in Canada: System-Level and Individual Measures of Performance and Outcomes
Abstract Number: 536

Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World Data from the St. Gallen Cohort

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].